Mannkind

No "professional Investor" was willing to say that the Afrezza trials would not be successful. But you are exactly right, Brentie, that AF has conceded this before and pointed out that there are still many more hurdles to success including approval and successful marketing. I say rejoice, as this is exactly why Afrezza still has considerable, even incredible, longterm upside potential. That is if it becomes as important a drug as Al Mann thinks is possible.